Shares of biopharmaceutical company Synlogic (NASDAQ:SYBX) are on the rise today after its product candidate SYNB1934 bagged an orphan drug designation from the U.S. Food and Drug Administration for the treatment of phenylketonuria (PKU).
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Next, Synlogic is planning to begin a Phase 3 trial of the drug in the first half of 2023. Impressively, SYNB1934 has also bagged a Rare Pediatric Disease designation in the U.S. as well as an orphan drug designation in Europe.
Today’s price gains come after a nearly 55.5% drop in Synlogic shares over the past year.
Read full Disclosure